TABLE 12. Clinically significant drug-drug interactions involving the rifamycins\*

| Drug class                    | Drugs whose concentrations are substantially decreased by rifamycins (references)   | Comments   |
|-------------------------------|---|--|
| Antiinfectives                | HIV-1 protease inhibitors (saquinavir, indinavir, nelfinavir, amprenavir, ritonavir, lopinavir/ritonavir) (1,20–25)                   | Can be used with rifabutin. Ritonavir, 400–600 mg twice daily, probably can be used with rifampin. The combination of saquinavir and ritonavir can also be used with rifampin.                               |
|                               | Nonnucleoside reverse transcriptase inhibitors<br>Delavirdine ( <i>26,27</i> )<br>Nevirapine ( <i>28</i> )<br>Efavirenz ( <i>29</i> ) | Delavirdine should not be used with any rifamycin. Doses of nevirapine (28) and efavirenz (29) need to be increased if given with rifampin, no dose increase needed if given with rifabutin (5).             |
|                               | Macrolide antibiotics (clarithromycin, erythromycin) (30–32)  | Azithromycin has no significant interaction with rifamycins.   |
|                               | Doxycycline (33)  | May require use of a drug other than doxycycline.  |
|                               | Azole antifungal agents (ketoconazole, itraconazole, voriconazole) (34–38)  | Itraconazole, ketoconazole, and voriconazole concentrations may be subtherapeutic with any of the rifamycins. Fluconazole can be used with rifamycins, but the dose of fluconazole may have to be increased. |
|                               | Atovaquone (39)   | Consider alternate form of Pneumocystis carinii treatment or prophylaxis.  |
|                               | Chloramphenicol (40)  | Consider an alternative antibiotic.  |
|                               | Mefloquine (41)   | Consider alternate form of malaria prophylaxis.  |
| Hormone therapy               | Ethinylestradiol, norethindrone (42–44)   | Women of reproductive potential on oral contraceptives should be advised to add barrier method of contraception when taking a rifamycin.   |
|                               | Tamoxifen (45)  | May require alternate therapy or use of a nonrifamycin-containing regimen.   |
|                               | Levothyroxine (46,47)   | Monitoring of serum TSH recommended; may require increased dose of levothyroxine.  |
| Narcotics                     | Methadone (48,49)   | Rifampin and rifapentine use may require methadone dose increase; rifabutin infrequently causes methadone withdrawal.  |
| Anticoagulants                | Warfarin (50)   | Monitor prothrombin time; may require two- to threefold dose increase.   |
| Immunosuppressive agents      | Cyclosporine, tacrolimus (51–53)  | Rifabutin may allow concomitant use of cyclosporine and a rifamycin; monitoring of cyclosporine serum concentrations may assist with dosing.   |
|                               | Corticosteroids (54–57)   | Monitor clinically; may require two- to threefold increase in corticosteroid dose (58  |
| Anticonvulsants               | Phenytoin (59), lamotrigine (60)  | Therapeutic drug monitoring recommended; may require anticonvulsant dose increase.   |
| Cardiovascular<br>agents      | Verapamil (61), nifedipine (62,63), diltiazem (a similar interaction is also predicted for felodipine and nisoldipine)                | Clinical monitoring recommended; may require change to an alternate cardiovascular agent.  |
|                               | Propranolol (64), metoporol (65)  | Clinical monitoring recommended; may require dose increase or change to an alternate cardiovascular drug.  |
|                               | Enalapril (66), Iosartan (67)   | Monitor clinically; may require a dose increase or use of an alternate cardiovascul drug.  |
|                               | Digoxin (among patients with renal insufficiency) (68), digitoxin (69)  | Therapeutic drug monitoring recommended; may require digoxin or digitoxin dose increase.   |
|                               | Quinidine (70,71)   | Therapeutic drug monitoring recommended; may require quinidine dose increase.  |
|                               | Mexilitine (72), tocainide (73), propafenone (15)   | Clinical monitoring recommended; may require change to an alternate cardiovascular drug.   |
| Bronchodilators               | Theophylline (74)   | Therapeutic drug monitoring recommended; may require theophylline dose increase.   |
| Sulfonylurea<br>hypoglycemics | Tolbutamide, chlorpropamide, glyburide, glimepiride, repaglinide ( <i>75–79</i> )   | Monitor blood glucose; may require dose increase or change to an alternate hypoglycemic drug.  |
| Hypolipidemics                | Simvastatin (80), fluvastatin (81)  | Monitor hypolipidemic effect; may require use of an alternate hypolipidemic drug.  |
| Psychotropic drugs            | Nortriptyline (82)  | Therapeutic drug monitoring recommended; may require dose increase or change to alternate psychotropic drug.   |
|                               | Haloperidol (83), quetiapine (84)   | Monitor clinically; may require a dose increase or use of an alternate psychotropic drug.  |
|                               | Benzodiazepines (e.g., diazepam [85], triazolam [86]), zolpidem (87), buspirone (88)  | Monitor clinically; may require a dose increase or use of an alternate psychotropic drug.  |

<sup>\*</sup> For reference citations refer to Section 7.2.